Company
Company Overview
Board of Directors
Executive Team
Advisory Board
Pipeline
Product Overview
AR-301 (Salvecin
®
)
AR-320 (Suvratoxumab)
AR-501 (Panaecin
™
)
AR-712 (COVID-19 mAb)
AR-701 (COVID-19 mAb)
Preclinical
AR-401
Out-licensed Products
AR-105 (Aerucin
®
)
AR-101 (Aerumab
™
)
AR-201
TECHNOLOGY
Technology Overview
APEX
TM
MabIgX
®
Therapeutic Targets
HAP / VAP
VAP Prevention
Cystic Fibrosis
COVID-19 Disease
Investors
Welcome
Corporate Governance
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Interactive Chart
Investment Calculator
Historical Stock Price
Analyst Coverage
Events and Webcasts
Publications and Posters
Investor alerts
Investor Inquiries
Contact Us
Contact Us
Careers
Company
Company Overview
Board of Directors
Executive Team
Advisory Board
Pipeline
Product Overview
AR-301 (Tosatoxumab)
AR-320 (Suvratoxumab)
AR-501 (Panaecin
™
)
AR-712 (COVID-19 mAb)
AR-701 (COVID-19 mAb)
Preclinical
AR-401
Out-licensed Products
AR-105 (Aerucin
®
)
AR-101 (Aerumab
TM
)
AR-201
TECHNOLOGY
Overview
MabIgX
®
Therapeutic Targets
HAP / VAP
VAP Prevention
Cystic Fibrosis
COVID-19 Disease
Investors
Welcome
Corporate Governance
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Interactive Chart
Investment Calculator
Historical Stock Price
Analyst Coverage
Events and Webcasts
Publications and Posters
Investor alerts
Investor Inquiries
Contact Us
Contact Us
Careers
Search:
Investors
SEC Filings
Select the filing type and date range you wish to view from the drop-down menus below.
Aridis Pharmaceuticals
Year
Trailing 12-Months
Calendar Year 2024
Calendar Year 2023
Calendar Year 2022
Calendar Year 2021
Calendar Year 2020
Calendar Year 2019
Calendar Year 2018
Calendar Year 2016
Calendar Year 2015
Calendar Year 2014
View
All Filings
Annual Filings
Quarterly Filings
Current Filings
Registration Statements
Section 16
Proxy & Information Statements
Other
Form
Description
Date
Format
D
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Nov 24, 2015
Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in HTML.
Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in DOC file.
Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in PDF file.
Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in XLS file.